This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

V5

Immune Network Ltd.

Drug Names(s): V5 Immunitor

Description: V5 is derived from pooled blood of hepatitis B and C carriers by employing Immunitor's proprietary technology. The process of manufacturing involves heat- and chemical inactivation with subsequent formulation into a tablet.

V5 is currently approved in Ukraine as an immunomodulating supplement.

Deal Structure: V5 was originally developed by Immunitor.

In September 2010, Immune Network entered into a letter of intent to acquire Immunitor oral vaccine technology and products.


V5 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug